Patients’ Preferences for Adjunctive Parkinson’s Disease Treatments: A Discrete-Choice Experiment by Serbin M, Marras C, Mansfield C, Leach C, Yonan C, Sheehan M, Donnelly A, Klepitskaya O

Get full text

Anticipating Tomorrow: Tailoring Parkinson's Symptomatic Therapy Using Predictors of Outcome by Postuma, RB, Weintraub, D, Simuni, T, Rodríguez‐Violante, M, Leentjens, AF, Hu, MT, Espay, AJ, Erro, R, Dujardin, K, Bohnen, NI, Berg, D, Mestre, TA, Marras, C

Investigating voice as a biomarker for leucine-rich repeat kinase 2-associated Parkinson’s disease by Arora, S, Visanji, N, Mestre, T, Tsanas, A, Aldakheel, A, Connolly, B, Gasca-Salas, C, Kern, D, Jain, J, Slow, E, Faust-Socher, A, Lang, A, Little, M, Marras, C

Mild cognitive impairment as a risk factor for Parkinson's disease dementia by Hoogland, J, Boel, JA, de Bie, RMA, Geskus, RB, Schmand, BA, Dalrymple-Alford, JC, Marras, C, Adler, CH, Goldman, JG, Tröster, AI, Burn, DJ, Litvan, I, Geurtsen, GJ

Risk of Parkinson's disease dementia related to level I MDS PD-MCI by Hoogland, J, Boel, JA, De Bie, RMA, Schmand, BA, Geskus, RB, Dalrymple-Alford, JC, Marras, C, Adler, CH, Weintraub, D, Junque, C, Pedersen, KF, Mollenhauer, B, Goldman, JG, Tröster, AI, Burn, DJ, Litvan, I, Geurtsen, GJ